Welcome to the first edition of the Warren Roundup, wherein an attempt is made to summarize accomplishments by members of the Warren Family Research Center for Drug Discovery. In addition, you will find below a succinct summary of the services provided by each of the three scientific cores (synthesis, computational, and biological). Not only do I invite you to provide updates for inclusion in upcoming issues, but I also encourage you to learn more about the Warren Center cores and how they can help expedite your research.…
The Indiana Clinical and Translational Sciences Institute (CTSI), a research partnership among Indiana University, Purdue University and the University of Notre Dame, has launched a new program called “All IN for Health” to help grow public awareness of the state’s current health challenges and to invite the public’s participation into research studies taking place at our academic partner institutions.
Indiana’s preeminent research universities are collaborating through the Indiana Clinical and Translational Sciences Institute (CTSI), which has recently been awarded more than $33 million in renewed National Institutes of Health (NIH) funding for the next five years.
Brian Blagg, Ph.D., currently the Lester and Betty Mitscher Professor of Medicinal Chemistry at the University of Kansas, will join the University of Notre Dame as the incoming director of the Warren Family Research Center for Drug Discovery and Development and the Charles Huisking Professor of Chemistry & Biochemistry, according to Mary E. Galvin, William K. Warren Dean of the College of Science.
Researchers have discovered a way to make influenza visible to the naked eye, by engineering dye molecules to target a specific enzyme of the virus.
There are currently four open Indiana Clinical and Translational Sciences Institute grant opportunities.
The Indiana CTSI is seeking applicants for the Collaboration in Translational Research (CTR) Pilot Grant Program. The objective of the Indiana CTSI CTR pilot grant program is to foster and encourage collaboration across the Indiana CTSI partner institutions (IU, Purdue, and Notre Dame) and to initiate or continue translational research projects that have very strong and immediate potential to develop into larger, externally funded research programs, or generate novel intellectual property (IP).
The WHO names Tuberculosis (TB) as one of the top 10 causes of death worldwide and over 95 percent of those deaths occur in low- and middle-income countries. To improve the global health community’s understanding of TB and provide information that could help treat it, Notre Dame researchers have developed a new strain of the bacteria along with a new method to better study this deadly disease.
Professsor Marv Miller presented the seminar, “Conjugation of an acinetobacter selective sideophore to Daptomycin generates a sideromycin with potent activity against acinetobacter baumannii” at the Antimicrobial Drug Discovery Symposium at the Solutions for Drug-Resistant Infections (SDRI) conference in Brisbane, Australia, April 3-5. SDRI 2017 brought together leading scientific, medical and…
The College is thrilled to announce that Brian Blagg (currently the Lester and Betty Mitscher Professor of Medicinal Chemistry at Kansas), will be joining the Department of Chemistry & Biochemistry this Fall and assuming the role of Director of the Warren Family Research Center for Drug Discovery & Development. …
February 28, 2017 - For the first time, the World Health Organization (WHO) published a list of “priority pathogens” which constitute a current and extreme threat to human health. WHO is seeking to promote new efforts in the discovery and development of new antibiotics to address a growing threat of antibiotic resistance.…
Coinciding with the World Rare Disease Day, Notre Dame acknowledges a recent, generous gift from Notre Dame parents David and Cathleen Reisenauer of Morgan Hill, Calif., which will allow the Warren Family Research Center for Drug Discovery and Development to initiate a new area of research, focusing on the rare disease glycogen storage disease type III (GSDIII), also known as Cori Disease.
The University of Notre Dame’s Warren Family Research Center for Drug Discovery and Development is focusing on collaboration, as it continues a rich history in therapeutic discovery.
Rare Disease Day takes place annually on the last day of February. Its goal is to raise awareness amongst the general public and policy-makers. Global Genes maintains the RARE List™ of 7,000 rare diseases defined in the United States where a prevalence of less than 200,000 cases is the primary criteria. With about 25M Americans affected by a rare disease and the potential to increase our understanding of more common afflictions, rare disease research is a key to better health for all of us.…
For decades, professor Paul Helquist has partnered with colleagues in Sweden to send undergraduate and graduate chemistry students to each others’ laboratories—around 50 in total—to perform research at Notre Dame, the University of Stockholm, Gothenburg University, the Royal Institute of Technology in Stockholm as well as the Astra Zeneca pharmaceutical lab near Gothenburg. Students from Notre Dame obtain valuable experience working in an international lab in a country which has a long-standing, strong program in science and engineering, particularly chemistry.
The Office of Technology Transfer (OTT) is now accepting nominations for the 1st Source Bank Technology Commercialization competition. The winner will be revealed at the seventh annual commercialization event on April 18, 2017, and will receive a $20,000 cash award.
Gaining access to important biopharmaceuticals needed to treat illnesses and autoimmune diseases is one of the biggest obstacles developing countries face. Now, a study led by Matthew Webber, assistant professor in Notre Dame’s Department of Chemical and Biomolecular Engineering, and appearing in the Proceedings of the National Academy of Sciences reveals a new way to improve the stability of common protein drugs and extend shelf life.
Diabetes is a metabolic disease in which the body has an inability to produce enough insulin. In the United States alone, it is estimated that the illness affects nearly 30 million diagnosed and undiagnosed people, and treatment often includes patients using an intravenous or IV method to get insulin into their system. This uncomfortable and inconvenient form of treatment can require anywhere from two to four injections a day, but a Notre Dame researcher is working to combat this problem with a less frequent, oral delivery system.
Each year, SPARK, a Stanford University initiative that provides the education and mentorship in order to advance research discoveries from the bench to the bedside, hosts a diverse group to participate in a 12-day training course in biotech innovation and entrepreneurship. The program provides an understanding of how biotechnology products, such as medical devices, food science, and general medical science, and companies are created, established, managed, advertised, and funded. Ricardo Romero, graduate student of the Integrated Biomedical Sciences program and researcher in the Harper Cancer Research Institute, had the opportunity to attend the program through the Indiana Clinical and Translational Sciences Institute (Indiana CTSI).
SDRI 2017 is a multi-disciplinary scientific conference focused on Solutions for Drug Resistant Infections. This inaugural conference theme is New Drugs for Drug-Resistant Infections. The conference will take place at the Brisbane Convention and Exhibition Centre in Australia from 3 - 5 April, 2017.…